TABLE 2.
Comprehensive information about the effects of myricetin in animal models Alzheimer’s disease.
| Pharmacological effect | Object | Drug administration | Possible mechanisms | References |
|---|---|---|---|---|
| Suppress streptozotocin-induced memory impairment | Rat | *5, 10 mg/kg | *Increase neuronal numbers in the hippocampus | Ramezani et al. (2016) |
| *i.p | ||||
| *1 day before stereotactic surgery, 21 days | ||||
| Suppress D-galactose-induced memory impairment | Mouse | *100 mg/kg | *Up-regulate p-ERK1/2/CREB | Lei et al. (2012) |
| *i.g | *Increase SOD activity | |||
| *once daily, 8 weeks | *Decrease TBARS levels | |||
| Suppress scopolamine-induced decrease in platform crossings and swimming time spent in the target quadrant in the Morris Water Maze test | Mouse | *25, 50 mg/kg | *Reduce MDA levels and AChE activity, and increase SOD, GPx, catalase activity in the hippocampus | Wang et al. (2017) |
| *i.g | ||||
| *once daily, 6 days | ||||
| Suppress Aβ1-42-induced nuclear fragmentation and caspase-3 activation | Cortical neurons | *0.3, 1, 3, 10 μM | *Promote ADAM10 expression | Shimmyo et al., 2008 |
| Reduce Aβ1-40/Aβ1-42 levels | *Pretreatment 24 h along with 24 h of simultaneous treatment | *Inhibit BACE-1 activity | ||
| Reverse scopolamine-induced increase in iron contents in the hippocampus | mouse | *25, 50 mg/kg | *Chelate intracellular Fe2+ | Wang et al. (2017) |
| *i.g | *Inhibit TrR1 expression | |||
| *Once daily, 6 days | — |